MedTrace Logo

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-01-14

No results posted yet for this study

Summary

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Conditions

  • Castrate Resistant Prostate Cancer
  • NUT Carcinoma
  • Chronic Myelomonocytic Leukemia
  • Myelofibrosis

Interventions

DRUG

EP31670

EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.

Sponsors & Collaborators

  • Epigenetix, Inc.

    lead INDUSTRY

Principal Investigators

  • Judy Chiao, MD · Epigenetix, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-21
Primary Completion
2025-05-31
Completion
2025-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05488548 on ClinicalTrials.gov